Please try another search
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Elisabeth Svanberg | 63 | 2017 | Independent Director |
Richard C. Dart | - | 2018 | Member of Scientific Advisory Board |
Laura James | - | 2018 | Member of Scientific Advisory Board |
James Dear | - | - | Member of Scientific Advisory Board |
Gunilla Osswald | 63 | 2017 | Independent Director |
Mats Peter Blom | 59 | 2021 | Chairman of the Board |
Thomas Lonngren | 74 | 2021 | Director |
Behshad Sheldon | 61 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review